1887

Abstract

There is an urgent need for effective therapies against bacterial infections, especially those caused by antibiotic-resistant Gram-negative pathogens.

Synergistic combinations of existing antimicrobials show promise due to their enhanced efficacies and reduced dosages which can mitigate adverse effects, and therefore can be used as potential antibacterial therapy.

In this study, we sought to characterize the interaction of 5-nitrofurans, vancomycin and sodium deoxycholate (NVD) against pathogenic bacteria.

The synergy of the NVD combination was investigated in terms of growth inhibition and bacterial killing using checkerboard and time-kill assays, respectively.

Using a three-dimensional checkerboard assay, we showed that 5-nitrofurans, sodium deoxycholate and vancomycin interact synergistically in the growth inhibition of 15 out of 20 Gram-negative strains tested, including clinically significant pathogens such as carbapenemase-producing , and , and interact indifferently against the Gram-positive strains tested. The time-kill assay further confirmed that the triple combination was bactericidal in a synergistic manner.

This study demonstrates the synergistic effect of 5-nitrofurans, sodium deoxycholate and vancomycin against Gram-negative pathogens and highlights the potential of the combination as a treatment for Gram-negative and Gram-positive infections.

Funding
This study was supported by the:
  • CatrinaOlivera , Massey University
  • CatrinaOlivera , Massey University (NZ) PhD Scholarship
  • JasnaRakonjac , PSAF stage II grant from MBIE and Massey University
  • JasnaRakonjac , Ann and Bryce Carmine
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001304
2021-01-15
2021-02-26
Loading full text...

Full text loading...

/deliver/fulltext/jmm/10.1099/jmm.0.001304/jmm001304.html?itemId=/content/journal/jmm/10.1099/jmm.0.001304&mimeType=html&fmt=ahah

References

  1. Breijyeh Z, Jubeh B, Karaman R. Resistance of Gram-negative bacteria to current antibacterial agents and approaches to resolve it. Molecules 2020; 25: 1340 [CrossRef]
    [Google Scholar]
  2. World Health Organization Prioritization of Pathogens to Guide Discovery, Research and Development of New Antibiotics for Drug-Resistant Bacterial Infections, Including Tuberculosis Geneva, Switzerland: World Health Organization; 2017
    [Google Scholar]
  3. World Health Organization Antibacterial Agents in Clinical Development: an Analysis of the Antibacterial Clinical Development Pipeline 2019 Geneva, Switzerland: World Health Organization; 2019
    [Google Scholar]
  4. McCalla DR, Voutsinos D. On the mutagenicity of nitrofurans. Mutat Res-Fund Mol M 1974; 26: 3 16 [CrossRef]
    [Google Scholar]
  5. Obaseiki-Ebor EE, Akerele JO. Nitrofuran mutagenicity: induction of frameshift mutations. Mutat Res Lett 1986; 175: 149 152 [CrossRef]
    [Google Scholar]
  6. Ny S, Edquist P, Dumpis U, Gröndahl-Yli-Hannuksela K, Hermes J et al. Antimicrobial resistance of Escherichia coli isolates from outpatient urinary tract infections in women in six European countries including Russia. J Glob Antimicrob Re 2019; 17: 25 34 [CrossRef]
    [Google Scholar]
  7. Raja NS. Oral treatment options for patients with urinary tract infections caused by extended spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae. J Infect Public Heal 2019; 12: 843 846 [CrossRef]
    [Google Scholar]
  8. Kwon DH, Lee M, Kim JJ, Kim JG, El-Zaatari FAK et al. Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: Prevalence and role of genes involved in metronidazole resistance. Antimicrob Agents Chemother 2001; 45: 306 308 [CrossRef]
    [Google Scholar]
  9. Choi YI, Jeong S-H, Chung J-W, Park DK, Kim KO et al. Rifabutin and furazolidone could be the candidates of the rescue regimen for antibiotic-resistant H. pylori in Korea. Can J Infect Dis Med 2019; 2019: 1 7 [CrossRef]
    [Google Scholar]
  10. Zamani M, Rahbar A, Shokri-Shirvani J. Resistance of Helicobacter pylori to furazolidone and levofloxacin: A viewpoint. WJG 2017; 23: 6920 6922 [CrossRef]
    [Google Scholar]
  11. Vass M, Hruska K, Fránek M. Nitrofuran antibiotics: a review on the application, prohibition and residual analysis. Vet Med (Praha) 2008; 53: 469 500 [CrossRef]
    [Google Scholar]
  12. Filippone EJ, Kraft WK, Farber JL. The nephrotoxicity of vancomycin. Clin Pharmacol Ther 2017; 102: 459 469 [CrossRef]
    [Google Scholar]
  13. Marinho DS, Huf G, Ferreira BLA, Castro H, Rodrigues CR et al. The study of vancomycin use and its adverse reactions associated to patients of a Brazilian university hospital. BMC Res Notes 2011; 4: 1 [CrossRef]
    [Google Scholar]
  14. Forouzesh A, Moise PA, Sakoulas G. Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob Agents Chemother 2009; 53: 483 486 [CrossRef]
    [Google Scholar]
  15. Roszell S, Jones C. Intravenous administration issues: a comparison of intravenous insertions and complications in vancomycin versus other antibiotics. J Infus Nurs 2010; 33: 112 118
    [Google Scholar]
  16. Van Bambeke F. Lipoglycopeptide antibacterial agents in gram-positive infections: a comparative review. Drugs 2015; 75: 2073 2095 [CrossRef]
    [Google Scholar]
  17. Crotty MP, Krekel T, Burnham C-AD, Ritchie DJ. New gram-positive agents: the next generation of oxazolidinones and lipoglycopeptides. J Clin Microbiol 2016; 54: 2225 2232 [CrossRef]
    [Google Scholar]
  18. Zeng D, Debabov D, Hartsell TL, Cano RJ, Adams S et al. Approved glycopeptide antibacterial drugs: mechanism of action and resistance. Cold Spring Harb Perspect Med 2016; 6: a026989 [CrossRef]
    [Google Scholar]
  19. Begley M, Gahan CGM, Hill C. The interaction between bacteria and bile. FEMS Microbiol Rev 2005; 29: 625 651 [CrossRef]
    [Google Scholar]
  20. Urdaneta V, Casadesús J. Interactions between bacteria and bile salts in the gastrointestinal and hepatobiliary tracts. Front Med 2017; 4: [CrossRef]
    [Google Scholar]
  21. Lin J, Sahin O, Michel LO, Zhang Q. Critical role of multidrug efflux pump CmeABC in bile resistance and in vivo colonization of Campylobacter jejuni . Infect Immun 2003; 71: 4250 4259 [CrossRef]
    [Google Scholar]
  22. Thanassi DG, Cheng LW, Nikaido H. Active efflux of bile salts by Escherichia coli . J Bacteriol 1997; 179: 2512 2518 [CrossRef]
    [Google Scholar]
  23. Venter H, Mowla R, Ohene-Agyei T, Ma S. RND-type drug efflux pumps from gram-negative bacteria: molecular mechanism and inhibition. Front Microbiol 2015; 06: [CrossRef]
    [Google Scholar]
  24. Prieto AI, Ramos-Morales F, Casadesús J. Repair of DNA damage induced by bile salts in Salmonella enterica . Genetics 2006; 174: 575 584 [CrossRef]
    [Google Scholar]
  25. Hernández SB, Cota I, Ducret A, Aussel L, Casadesús J. Adaptation and preadaptation of Salmonella enterica to bile. PLoS Genet 2012; 8: e1002459 [CrossRef]
    [Google Scholar]
  26. Le VVH, Olivera C, Spagnuolo J, Davies IG, Rakonjac J. In vitro synergy between sodium deoxycholate and furazolidone against enterobacteria. BMC Microbiol 2020; 20: [CrossRef]
    [Google Scholar]
  27. Zhou A, Kang TM, Yuan J, Beppler C, Nguyen C et al. Synergistic interactions of vancomycin with different antibiotics against Escherichia coli: trimethoprim and nitrofurantoin display strong synergies with vancomycin against wild-type E. coli . Antimicrob Agents Chemother 2015; 59: 276 281 [CrossRef]
    [Google Scholar]
  28. Clinical and Laboratory Standards Institute Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically , 10th ed. M07-A10 Wayne, PA: Clinical and Laboratory Standards Institute; 2015
    [Google Scholar]
  29. Campbell J. High-throughput assessment of bacterial growth inhibition by optical density measurements. Curr Protoc Chem Biol 2011; 3:
    [Google Scholar]
  30. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Dieases (ESCMID) Eucast definitive document E.Def 1.2, may 2000: terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. Clin Microbiol Infect 2000; 6: 503 508
    [Google Scholar]
  31. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1 [CrossRef]
    [Google Scholar]
  32. Bruniera F, Ferreira F, Saviolli L, Bacci M, Feder D. The use of vancomycin with its therapeutic and adverse effects: a review. Eur Rev Med Pharmacol Sci 2015; 19: 694 700
    [Google Scholar]
  33. PL H, Yuan YH, Yue TL, Guo CF. Bile acid patterns in commercially available oxgall powders used for the evaluation of the bile tolerance ability of potential probiotics. PLoS One 2018; 13: e0192964-e
    [Google Scholar]
  34. Bollenbach T. Antimicrobial interactions: mechanisms and implications for drug discovery and resistance evolution. Curr Opin Microbiol 2015; 27: 1 9 [CrossRef]
    [Google Scholar]
  35. Hammes WP, Neuhaus FC. On the mechanism of action of vancomycin: inhibition of peptidoglycan synthesis in Gaffkya homari . Antimicrob Agents Chemother 1974; 6: 722 728 [CrossRef]
    [Google Scholar]
  36. Nieto M, Perkins HR. Modifications of the acyl-D-alanyl-D-alanine terminus affecting complex-formation with vancomycin. Biochem J 1971; 123: 789 803 [CrossRef]
    [Google Scholar]
  37. Gunn JS. Mechanisms of bacterial resistance and response to bile. Microbes Infect 2000; 2: 907 913 [CrossRef]
    [Google Scholar]
  38. Raphael BH, Pereira S, Flom GA, Zhang Q, Ketley JM et al. The Campylobacter jejuni response regulator, CbrR, modulates sodium deoxycholate resistance and chicken colonization. J Bacteriol 2005; 187: 3662 3670 [CrossRef]
    [Google Scholar]
  39. Paul S, Alegre KO, Holdsworth SR, Rice M, Brown JA et al. A single-component multidrug transporter of the major facilitator superfamily is part of a network that protects Escherichia coli from bile salt stress. Mol Microbiol 2014; 92: 872 884 [CrossRef]
    [Google Scholar]
  40. Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY antimicrobial surveillance program (1998–2004). Diagn Microbiol Infect Dis 2007; 57: 7 13 [CrossRef]
    [Google Scholar]
  41. Spagnuolo J, Opalka N, Wen WX, Gagic D, Chabaud E et al. Identification of the gate regions in the primary structure of the secretin pIV. Mol Microbiol 2010; 76: 133 150 [CrossRef]
    [Google Scholar]
  42. Williamson DA, Sidjabat HE, Freeman JT, Roberts SA, Silvey A et al. Identification and molecular characterisation of New Delhi metallo-β-lactamase-1 (NDM-1)- and NDM-6-producing Enterobacteriaceae from New Zealand hospitals. Int J Antimicrob Agents 2012; 39: 529 533 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001304
Loading
/content/journal/jmm/10.1099/jmm.0.001304
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error